APAparna Pal

Aparna Pal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aparna Pal has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?

    by Harsha Anuruddhika Dissanayake, Bronwen Warner, Anne‐Marie Hannon, Riccardo Pofi, Radu Mihai, Tim James, Brian Shine, David William Ray, Jeremy W. Tomlinson, Aparna Pal

    Objective: Primary aldosteronism (PA) is the commonest secondary cause of hypertension but case‐detection remains a challenge. Screening is usually performed in secondary care using an aldosterone:renin ratio (ARR) measurement. Here, we describe the outcomes of screening in primary care, in Oxfordshire, UK.Design: Retrospective observational study.Patients: Adults screened for PA in primary care services in Oxford between 2008 and 2022.Measurements: ARR test results in primary care and outcomes of secondary care evaluation (ARR, saline infusion test, final diagnosis). Primary care and secondary care ARR tests were compared for correlation, concordance and performance in predicting PA.Results: Among 2915 adults screened in primary care, 455 were referred to secondary care and 107 (3.7% of total population screened) were diagnosed with PA. Primary care ARR showed strong correlation with secondary care ARR (r = 0.841, p < 0.001). Area under the ROC curve to predict PA was 0.81 (95% CI 0.77–0.86) for primary care ARR testing. Primary care ARR cut‐off of ≥ 30 pmol/mU showed comparable sensitivity (91.7% vs 92.1%, p = 0.467) to and modest concordance (Kappa 0.583, p < 0.001) with secondary care ARR. Use of beta‐blockers were associated with higher risk of false positive test result (OR 3.5, 95% CI 1.1–12.0, p = 0.042).Conclusions: Screening for PA in primary care with ARR is feasible with modest concordance and comparable sensitivity to secondary care testing. Simple referral criteria and raising awareness among primary care colleagues could ensure appropriate referral to secondary care.


  • Open Access

    Copeptin and the syndrome of inappropriate antidiuresis (SIAD) after pituitary transsphenoidal surgery

    by Agathoklis Efthymiadis, Riccardo Pofi, Hussam Rostom, Tim James, Brian Shine, Nish Guha, Simon Cudlip, Mirjam Christ‐Crain, Aparna Pal

    Objective: This study evaluates the predictive value of copeptin for syndrome of inappropriate antidiuresis (SIAD) postpituitary transsphenoidal surgery (TSS).Design: Data from 133 consecutive patients undergoing TSS (November 2017–October 2022) at Oxford University Hospitals NHS trust are presented in this retrospective study.Methods: Logistic regression (LR) and receiver operating characteristic (ROC) curves were performed to evaluate the diagnostic utility of copeptin. The Mann–Whitney U test was used to compare copeptin levels between the SIAD and no SIAD groups.Results: Fourteen patients (10.8%) developed SIAD. Copeptin was available in 121, 53 and 87 patients for Days 1, 241 and 8 post‐TSS, respectively. LR for Day 1 copeptin to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 42 0.84–1.20, p = .99), area under‐ROC curve (AUC) was 0.49; Day 2 copeptin OR was 0.65 (95%CI 0.39–1.19, 43 p = .77), AUC was 0.57 LR for Day 1 sodium to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 0.85–1.21, p = .99), AUC was 0.50.Conclusions: In conclusion, our data provide no evidence for copeptin as a predictive marker for post‐TSS SIAD.


  • Counselling for adrenal insufficiency for patients on long term steroids amongst physicians and patients

    by Hannon Anne Marie, Frances Rose, Andev Rajinder Singh, Helen Loo, Ann Marland, Aparna Pal

    Patients with adrenal insufficiency (AI) should be informed about ‘sick day rules’ and risk of a life-threatening adrenal crisis if corticosteroids are abruptly stopped or if the steroid dose is inadequate. Aims and Methods: To assess current practice with regard to steroid advice given across medical specialties at Oxford University Hospital Trust. To assess patient knowledge both in a specialist Endocrine department and in a medical specialty where steroids are commonly prescribed (Rheumatology). An online survey was used for the clinician survey and 5-point question survey for the patient survey. Results: Forty-one doctors across training grades (37% IMT, 24% registrars, 39% consultants) from a range of specialties completed the survey. 56% of respondent medics stated they usually/always counselled regarding sick day rules when starting long term steroids; 20% of respondents said they rarely/never advised patients on steroid sick day rules. Only 34% of the doctors surveyed were providing the NHS steroid alert card. Sixty patients attending the endocrine clinic (34F,26M; 21 patients primary AI, 30 patients secondary AI and 9 patients with tertiary AI secondary to long-term steroid use) were surveyed and only one patient was not familiar with sick day rules. 83% (50/60) patients carried a steroid card and 70% (42/60) wore a medical alert. 25% reported a delay in receiving steroids when unwell in the past. By contrast, 0/20 Rheumatology patients had received a steroid alert card; and 40% (8/20) were unaware of steroid sick day rules; 10%(2/20)patients had experienced an adrenal crisis. Conclusions: There is a need for patient steroid education training across the medical specialties so that all patients at risk of adrenal insufficiency are identified and educated appropriately about the risk of adrenal crisis. As Endocrinologists we should reach out to Trust colleagues in other specialties to help deliver this education.

  • Coexistence of cranial diabetes insipidous and heart failure with reduced ejection fraction: a case report presenting challenges and unique therapeutic opportunities

    by Agathoklis Efthymiadis, P Gamble James H, Aparna Pal

    History: We present the case of a 47-year-old man with heart failure (HF) and cranial diabetes insipidus (CDI) secondary to Langerhans-cell-histiocytosis. In the context of worsening HF with increasing shortness of breath and fluid retention, careful desmopressin dose reduction provided adequate aquaresis to restore euvolemia, obviating the need for usual diuretic treatments. Investigations: Echocardiography and a cardiac MRI revealed a non-dilated but severely impaired left ventricle (ejection-fraction 35%). His right ventricle was impaired but non- dilated. Sodium, paired osmolarities were within reference range throughout follow-up. Treatment: Careful reduction of desmopressin from maintenance dose of 200 mg thrice-daily to 200 mg twice-daily allowed for adequate aquaresis and resolution of worsening HF symptoms. Iatrogenic diuresis was not indicated. Desmopressin adjustment manoeuvres were adequate to restore euvolemia, with urine output averaging 2-2.5 litres. After resolution of HF symptoms, desmopressin was switched back to 200 mg thrice-daily. Maximum tolerated Losartan dose was 50 mg. Beta-blockade, mineralocorticoid-receptor or angiotensin-receptor- neprilysin inhibition were not tolerated. SGLT-2 inhibition has not been trialled yet. Conclusions: The co-existence of CDI and HF presents both challenges and unique therapeutic opportunities. Desmopressin dose manoeuvres produced adequate aquaresis, leading to restoration of euvolemia and rapid symptomatic relief. Dizziness, polyuria, thirst limited tolerability of HF prognostication drugs. Close endocrinology and cardiology co-operation was key in avoiding admissions with decompensated HF. This case provides insights for novel drug development targets. Our patient has complete absence of V1a-receptor activity (absent endogenous vasopressin). V2-receptor activity is dose-dependent based on desmopressin manipulation. Inducing a similarly balanced V1a/V2-receptor activity state pharmacologically could translate to clinically meaningful aquaresis, obviating V1a-receptor induced deleterious vasoconstriction and cardiac remodelling. This could represent a novel HF treatment target, potentially more effective than selective V2- receptor antagonism (tolvaptan) associated with toxic V1a-receptor activation via rebound endogenous vasopressin release. Pecavaptan, a novel balanced oral V1a/V2-receptor antagonist is under development.

  • Feasibility of primary aldosteronism screening in primary care - prevalence and concordance with secondary care assessment

    by Hannon Anne Marie, Harsha Dissanayake, Bronwen Warner, Radu Mihai, Tim James, David Ray, Brian Shine, Aparna Pal

    Background: Primary aldosteronism (PA) is the commonest cause of secondary hypertension. Reported prevalence is about 30% in hypertensive population. Success of screening for PA in general practice (GP) is unknown. Expected challenges include laboratory access, transport issues and interfering medications. Aims: We aimed to report prevalence of PA in a large primary care cohort, the correlation between GP and in-hospital ARR and to assess if a change in renin assay affected rates of positive ARR detection. Methods: A retrospective analysis of individuals who had aldosterone-renin ratio (ARR) checked by their GP (GP-ARR) between January2012-December2021 was conducted. Reasons for testing and outcomes were retrieved from electronic records. Samples were assayed for aldosterone concentration ( pmol/l) and plasma renin activity (ng/ml/hour) before 2015 (positive if ARR > 1000) and for aldosterone (ng/dL) and direct renin concentrations (mU/l) (positive if ARR > 30) post-2015. Results: In total 3408 samples from 2615 patients were received from GPs (13.5% rejected due to delayed transit time). Three hundred and thirty-two (12.7% of screened population) had positive GP-ARR (men 183 [55.1%]), median age 53 years [IQR 44-64]). Among positively screened, 232 (70%) were referred to secondary care. Among those referred to Endocrinology (n=200), 68% (60/88) had positive hospital-ARR and 33.5% (67/200) had confirmed PA and were treated with adrenalectomy (n=22) or mineralocorticoid antagonists (n=45). GP-ARR post-2015 renin assay change had higher positivity rate [16.7% (262/1568) vs 6.6% (70/1047), P<0.001]. Conclusions: Screening ARR for PA in primary care is feasible with low sample rejection rates and good concordance to in-hospital testing. Renin assay methods should be considered when analysing ARR outcomes. Over a quarter of patients with positive ARR results were not referred to secondary care highlighting the importance of increasing awareness of the benefit of investigation and treatment in PA to Primary Care colleagues.

  • Open Access

    Post-pituitary surgery copeptin analysis as a ‘rule-out’ test for post-operative diabetes insipidus

    by Hussam Rostom, Sean Noronha, Bahram Jafar-Mohammadi, Christine May, Anouk Borg, Jane Halliday, Simon Cudlip, Tim James, Nishan Guha, Brian Shine, et al.

    Background: Diabetes insipidus (DI) is a recognised complication of pituitary surgery, with diagnosis requiring clinical observation aided by plasma and urine electrolytes and osmolalities. Copeptin is a stable surrogate marker of AVP release and has potential to facilitate prompt diagnosis of post-operative DI. This assay has been shown to accurately predict which patients are likely to develop DI following pituitary surgery. Objective: To determine whether copeptin analysis can be used to predict which patients are at risk of developing DI following trans-sphenoidal surgery (TSS). Methods: Seventy-eight patients undergoing TSS had samples taken for copeptin pre-operatively and at day 1 post-TSS. The majority of patients also had samples from day 2, day 8, and week 6 post-TSS. Results from patients who developed post-operative DI (based on clinical assessment, urine and plasma biochemistry and the need for treatment with DDAVP) were compared to those who did not. Patients with any evidence of pre-operative DI were excluded. Results: Of 78 patients assessed, 11 were clinically determined to have developed DI. Differences were observed between patients with DI and those without in post-operative samples. Of note, there was a significant difference in plasma copeptin at day 1 post-operation (p = 0.010 on Kruskal–Wallis test), with copeptin levels greater than 3.4 pmol/l helping to rule out DI (91% sensitivity, 55% specificity at this cut off). Conclusion: In the post-TSS setting, copeptin is a useful rule-out test in patients with values above a defined threshold, which may facilitate earlier decision making and shorter hospital stays.


  • Time from referral to definitive treatment in Cushing's syndrome

    by Amy Coulden, Simon Aylwin, Daniel Flanagan, Yaasir Mamoojee, Aparna Pal, Neil Gittoes, Helena Gleeson

    Rapid diagnosis and treatment of Cushing’s syndrome (CS) is essential for good outcomes. Current standards for appropriate timelines for referral are under review by NHSE. Data are required to substantiate standard setting. Knowledge of current referral pathways/processes are required to explore delays in accessing definitive surgical treatment. An audit of referral processes at Queen Elizabeth Hospital Birmingham was undertaken and further expanded to 4 additional tertiary centres in England. Data were collected on adult patients diagnosed with CS and referred for surgery at index hospitals between January 2018 and December 2019. Patients seen privately were excluded until seen in index hospital. Data were collected on demographics, initial referrer and referral pathway and dates of first clinic, subsequent referral to index hospital (if applicable), first index hospital clinic, MDT and definitive surgery. 72 patients were diagnosed with CS; 69 had definitive surgical treatment. 37 patients had pituitary CS, 34 adrenal CS, 1 had ectopic ACTH secretion. Demographics and referral pathways are outlined in table below. Results are given as median averages. Time from initial referral to secondary clinic (39.5 days in all patients, 45 days in pituitary and 35 days in adrenal patients) was shorter than those referred direct to index tertiary clinic (57 days in all-comers, 56 days in pituitary and 62 days in adrenal patients). However, total time from referral to tertiary clinic via secondary pathway was significantly longer (158.5 days in all, 140 days in pituitary and 171 in adrenal patients). The number of diagnostic tests performed in secondary care was 6 in each group. Time from referral to index hospital to MDT was 32, 61 and 22.5 days for all, pituitary and adrenal patients respectively. Time to definitive surgical treatment was 183, 178 and 180 days for all, pituitary and adrenal patients respectively. By mapping average timeline from referral to definitive surgical treatment in CS patients, we’ve highlighted areas of national and hospital-specific delays which can be improved for better patient outcomes. Both secondary and tertiary centres should organise more rapid reviews of patients with a potential diagnosis of CS and minimal investigation criteria should be set before secondary centres involve tertiary centres in management of CS patients. Table 1 All (n=72) Pituitary (n=31) Adrenal (n=34) Median age (years) 49 44 48 M:F ratio 17:55 8:29 8:26 Initial referrer GP 44(61.1%) 22(59.4%) 22(64.7%) Inpatient referral 25(34.7%) 13(35.1%) 12(35.3%) Initial clinic Secondary 44(61.1%) 20(54.1%) 24(70.6%) Index tertiary 22(30.6%) 14(37.8%) 7(20.6%)

  • Open Access

    Post-Operative Copeptin Analysis Predicts Which Patients Do Not Develop Diabetes Insipidus After Pituitary Surgery

    by Hussam Rostom, Sean Noronha, Bahram Jafar-Mohammadi, Christine May, Anouk Borg, Jane Halliday, Simon Cudlip, Tim James, Nishan Guha, Brian Shine, et al.

    Background: Diabetes insipidus (DI) is a recognised complication of pituitary surgery, with diagnosis requiring clinical observation aided by plasma and urine electrolytes and osmolalities. Copeptin is a stable surrogate marker of AVP release and has potential to facilitate prompt diagnosis of post-operative DI. This assay has been shown to accurately predict which patients are likely to develop DI following pituitary surgery. Objective: To determine whether copeptin analysis can be used to predict which patients are at risk of developing DI following transsphenoidal adenomectomy (TSA).Methods: 78 patients undergoing TSA had samples taken for copeptin pre-operatively and at day 1 post-TSA. The majority of patients also had samples from day 2, day 8, and week 6 post-TSA. Results from patients who developed post-operative DI (based on clinical assessment, urine and plasma biochemistry and the need for treatment with DDAVP) were compared to those who did not. Patients with any evidence of pre-operative DI were excluded.Results: Of 78 patients assessed, eleven were clinically determined to have developed DI. Differences were observed between patients with DI and those without in post-operative samples. Of note, there was a significant difference in plasma copeptin at day 1 post-operation (p=0.010 on Kruskal-Wallis test), with copeptin levels greater than 3.4 pmol/L helping to rule out DI (91% sensitivity, 55% specificity at this cut off).Conclusion: In the post-TSA setting, copeptin is a useful rule-out test in patients with values above a defined threshold, which may facilitate earlier decision making and shorter hospital stays.

  • Delayed diagnosis of T3 supplementation in a bodybuilder presenting with tachycardia and features of sepsis

    by Bronwen E Warner, Charles J Woodrow, Aparna Pal

    A 25-year-old man presented generally unwell to the emergency department. Initial assessment identified systemic inflammatory response syndrome markers with an insect bite as a potential source of infection and he was treated for presumed sepsis. Tachycardia persisted and baseline thyroid function testing showed undetectable free thyroxine and thyroid-stimulating hormone (TSH), prompting further endocrine investigation. Triiodothyronine (T3) was markedly raised with normal TSH receptor antibodies, and the patient later confessed to supplementary testosterone and T3 use as part of bodybuilding activities. Following counselling, thyroid function normalised and the patient returned to his usual health. This case describes the diagnostic work up in a case of persistent tachycardia caused by T3 supplementation, demonstrating the potential for endocrine supplementation by bodybuilders which may be poorly understood and recognised by clinicians. T3 supplementation should be considered and a thorough drug history obtained in bodybuilders presenting with symptoms of thyrotoxicosis and deranged thyroid function tests.